| Literature DB >> 34637059 |
Sarinya Puwanant1,2, Veraprapas Kittipibul3,4, Nattakorn Songsirisuk3,4, Sakun Santisukwongchote5, Patita Sitticharoenchai3,4, Pairoj Chattranukulchai3,4, Sudarat Satitthummanid3,4, Smonporn Boonyaratvej3,4.
Abstract
The aims of this study were to examine the prevalence of moderate to large (moderate-large) idiopathic pericardial effusion (i-PEF) in patients with hypertrophic cardiomyopathy (HCM) and to identify clinical and echocardiographic hemodynamic profiles associated with pericardial effusion. A total of 292 adult patients with HCM were studied. Fifteen patients with a history of factors associated with pericardial effusion including myocardial infarction, heart surgery or cardiac procedure within the last 12 months, autoimmune disease, hydralazine use, chronic kidney disease stage 3-4, tuberculosis, and malignancy were excluded. Of 277 eligible patients with HCM, 11 patients (4%) with moderate-large i-PEF were identified. Clinical tamponade was present in 1 patient. Compared to patients with HCM who had no or small pericardial effusion, patients with moderate-large i-PEF were younger and more likely to have right ventricular (RV) hypertrophy and reverse septal curvature. These patients also exhibited a greater maximal septal thickness, mean and systolic pulmonary pressure, and right atrial pressure (p < 0.05 for all). Pericardial fluid analysis and histopathological exams were performed in 7 and 3 patients, respectively. All examinations revealed transudative and nonspecific etiology of pericardial effusion. Idiopathic pericardial effusion and cardiac tamponade in patients with HCM was uncommon. The pathophysiology involved in pericardial effusion remains undetermined. Patients with moderate-large i-PEF frequently exhibited a phenotype of pulmonary hypertension and RV pressure overload.Entities:
Keywords: Hypertrophic cardiomyopathy; Pathology; Pericardial effusion
Mesh:
Year: 2021 PMID: 34637059 PMCID: PMC8888481 DOI: 10.1007/s10554-021-02424-8
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Fig. 1The prevalence of idiopathic pericardial effusion in patients with HCM
Clinical and echocardiographic characteristics by presence or absence of moderate to large pericardial effusion
| All | Moderate to large pericardial effusion | Non-significant pericardial effusion | p value | |
|---|---|---|---|---|
| Age | 63 ± 16 | 49 ± 16 | 63 ± 16 | 0.01* |
| Female | 161 (58%) | 6 (55%) | 155 (58%) | 0.81 |
| NYHA Class III–IV [n (%)] | 48 (17%) | 2 (18%) | 46 (18%) | 0.16 |
| Systolic blood pressure (mmHg) | 130 ± 19 | 131 ± 20 | 130 ± 19 | 0.88 |
| Diastolic blood pressure (mmHg) | 74 ± 11 | 74 ± 6 | 75 ± 11 | 0.50 |
| Atrial fibrillation [n (%)] | 36 (13%) | 1 (9%) | 35 (13%) | 0.69 |
| Major Phenotype [n (%)] | ||||
| Asymmetrical septal hypertrophy | 138 (50%) | 8 (73%) | 130 (49%) | 0.68 |
| Pure apical | 56 (20%) | 2 (18%) | 54 (20%) | |
| Mixed apical | 30 (11%) | 0 | 30 (12%) | |
| Concentric | 47 (17%) | 1 (9%) | 46 (17%) | |
| Localized/mid | 6 (2%) | 0 | 6 (2%) | |
| Reverse-curve septal morphology | 86 (31%) | 8 (72%) | 78 (29%) | 0.02* |
| Large pericardial effusion | 4 (1%) | 4 (36%) | 0 | < 0.01* |
| Beta blocker [n (%)] | 121 (73%) | 11 (100%) | 197 (74%) | 0.05 |
| Calcium channel blocker [n (%)] | 39 (14%) | 1 (9%) | 38 (14%) | 0.62 |
| Septal myectomy [n (%)] | 34 (12%) | 6 (54%) | 28 (10%) | < 0.01* |
| Alcohol septal ablation [n (%)] | 2 (1%) | 0 (0%) | 2 (1%) | 0.77 |
| Maximal septal thickness (mm) | 19 ± 5 | 24 ± 5 | 18 ± 5 | < 0.01* |
| Resting LVOT gradient > 30 mmHg [n (%)] | 60 (36%) | 3 (33%) | 57 (35%) | 0.88 |
| LVEDD (mm) | 43 ± 8 | 41 ± 9 | 43 ± 8 | 0.77 |
| LVEF (%) | 71 ± 12 | 71 ± 13 | 71 ± 12 | 0.88 |
| LAVI (ml/m2) | 39 ± 16 | 39 ± 13 | 39 ± 17 | 0.99 |
| RAVI (ml/m2) | 33 ± 16 | 40 ± 24 | 33 ± 15 | 0.42 |
| RV free wall thickness (mm) | 9 ± 3 | 10.3 ± 2.0 | 8.4 ± 2.7 | 0.01* |
| Estimated RAP (mmHg) | 7 ± 4 | 15 ± 5 | 6 ± 4 | < 0.01* |
| Estimated pulmonary arterial systolic pressure (mmHg) | 36 ± 11 | 48 ± 11 | 36 ± 11 | < 0.01* |
| Estimated mean pulmonary arterial pressure (mmHg) | 22 ± 6 | 29 ± 5 | 22 ± 6 | < 0.01* |
| Pulmonary hypertension (n,%) | 117 (42%) | 10 (90%) | 107 (40%) | < 0.01* |
| TAPSE (mm) | 17.9 ± 4.6 | 18.3 ± 4.3 | 18.0 ± 4.6 | 0.76 |
LV left ventricular; LVEDD left ventricular end diastolic diameter; LVEF Left ventricular ejection fraction; LAVI left atrial volume index; LVEDD left ventricular end diastolic diameter; LVOT left ventricular outflow tract; mm millimeter; NYHA New York Heart Association; RAP right atrial pressure; RAVI right atrial volume index; RV right ventricular; TAPSE tricuspid annular plane excursion
Fig. 2A massive circumferential pericardial effusion (asterisks) in a 40-year-old man with a hypertrophic cardiomyopathy (patient #2) demonstrated by transthoracic echocardiogram (a) and cardiovascular magnetic resonance imaging (b)
Clinical and cardiac imaging characteristics of HCM patients with pericardial effusion
| No | Age/gender | Effusion (mm) | Effusion | EF (%) | RV free wall thickness (mm) | Maximal thickness | Resting LVOT gradient | Phenotype | RAP (mmHg) | RVSP (mmHg) | ANA and RF | CMV IgM | Anti-HIV Ab | Pathological Exam | Pericardial fluid color | Pericardial fluid type | Pericardial fluid PCR for TB | Pericardial fluid culture for aerobe, TB, and fungus | Pericardial fluid cytology | Pericardial thickness by cardiac MRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 57 F | 17 | Moderate | 84 | 9.4 | 32 | 19 | ASH | 18 | 44 | Neg | Neg | Neg | Not performed | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
| 2 | 71 M | 36 | Large | 73 | 9.0 | 19 | 20 | ASH | 20 | 72 | Neg | Neg | Neg | Normal | Straw, clear | Transudate | Neg | Neg | Neg | N/A |
| 3 | 24 F | 13 | Moderate | 87 | 11.3 | 19 | 63 | ASH | 8 | 54 | Neg | Neg | Neg | Not performed | N/A | N/A | N/A | N/A | N/A | Normal |
| 4 | 40 M | 30 | Large | 90 | 13.0 | 31 | 40 | ASH | 20 | 39 | Neg | Neg | Neg | Normal | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
| 5 | 54 M | 12 | Moderate | 70 | 9.1 | 21 | 12 | Apical | 10 | 31 | Neg | Neg | Neg | Not performed | N/A | N/A | Neg | N/A | N/A | Normal |
| 6 | 56 M | 26 | Large | 76 | 7.0 | 30 | 18 | Apical | 15 | 49 | Neg | Neg | Neg | Not performed | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
| 7 | 51 M | 14 | Moderate | 65 | 9.2 | 22 | 23 | Concentric | 20 | 42 | Neg | N/A | Neg | Not performed | N/A | N/A | Neg | N/A | N/A | Normal |
| 8 | 21 F | 13 | Moderate | 45 | 10.0 | 21 | 15 | ASH | 15 | 51 | Neg | Neg | Neg | Not performed | N/A | N/A | N/A | N/A | N/A | Normal |
| 9 | 47 F | 23 | Large | 61 | 13.1 | 29 | 14 | ASH | 15 | 58 | Neg | Neg | Neg | Normal | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
| 10 | 52 F | 15 | Moderate | 68 | 12.0 | 20 | 25 | ASH | 15 | 53 | Neg | Neg | Neg | Not performed | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
| 11 | 67 M | 16 | Moderate | 65 | 11.0 | 22 | 66 | ASH | 3 | 39 | N/A | Neg | Neg | Not performed | Straw, clear | Transudate | Neg | Neg | Neg | Normal |
ANA antinuclear antibody; ASH asymmetrical septal hypertrophy; CMV cytomegalovirus; EF ejection fraction; F female; HIV Human Immunodeficiency Virus; LVOT left ventricular outflow tract; M male; mm millimeter; MRI magnetic resonance imaging; N/A not applicable; Neg negative; RAP right atrial pressure; RF rheumatoid factor; RV right ventricular; RVSP right ventricular systolic pressure; S systolic forward flow; TB tuberculosis
Fig. 3Example of pericardial histopathological findings of a 40-year-old patient who underwent surgical myectomy and pericardial biopsy. The pericardium revealed normal pericardial thickening and intact mesothelial cells with no active inflammation, granuloma, malignancy, or calcification